Page last updated: 2024-12-06

ripazepam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID33474
CHEMBL ID159298
CHEBI ID82529
SCHEMBL ID636179
MeSH IDM0053531

Synonyms (35)

Synonym
1-ethyl-3-methyl-8-phenyl-4,6-dihydropyrazolo[4,3-e][1,4]diazepin-5(1h)-one
1-ethyl-4,6-dihydro-3-methyl-8-phenylpyrazolo(4,3-e)(1,4)diazepin-5(lh)-one
ripazepam [usan:inn]
pyrazapon
ripazepamum [inn-latin]
pyrazolo(4,3-e)(1,4)diazepin-5(1h)-one, 1-ethyl-4,6-dihydro-3-methyl-8-phenyl-
brn 0819726
1-ethyl-4,6-dihydro-3-methyl-8-phenylpyrazolo(4,3-e)(1,4)diazepin-5(1h)-one
ccris 552
pyrazolo(4,3-e)(1,4)diazepin-5(1h)-one, 4,6-dihydro-1-ethyl-3-methyl-8-phenyl-
1-ethyl-1,4,5,6-tetrahydro-3-methyl-8-phenylpyrazolo(4,3-e)(1,4)diazepin-5-on
26308-28-1
D05733
ripazepam (usan/inn)
ci-683
ripazepam
1-ethyl-3-methyl-8-phenyl-4,6-dihydropyrazolo[4,3-e][1,4]diazepin-5-one
CHEMBL159298
cl-683
chebi:82529 ,
C19518
92000wh9c9 ,
unii-92000wh9c9
ripazepamum
SCHEMBL636179
ripazepam [iarc]
1-ethyl-4,6-dihydro-3-methyl-8-phenylpyrazolo[4,3-e][1,4]diazepin-5(1h)-one
ripazepam [usan]
ripazepam [inn]
DTXSID1021245
Q7335571
ci-683;pyrazapon.
CS-0067700
HY-118657
AKOS040749299

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" As rated by both physician and patient, ripazepam was found significantly superior to placebo at both dosage levels."( Ripazepam (CI-683): double-blind comparison with placebo in anxious patients.
Borgen, LA; Goodman, LI; Schneyer, JJ, 1976
)
1.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID40835Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor in synaptic membranes of rat cerebral cortex1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and interaction of 5-(substituted-phenyl)-3-methyl-6,7-dihydropyrazolo[4,3-e] [1,4]diazepin-8(7H)-ones with benzodiazepine receptors in rat cerebral cortex.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID409957Inhibition of bovine liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (50.00)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.13 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]